Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
May 30, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 30, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
May 29, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 29, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the following investor conferences in June: Jefferies 2019...
Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
May 16, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
May 13, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
May 02, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively–...
Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
April 17, 2019 16:25 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
April 08, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
March 18, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
March 07, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two...
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
February 28, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference on...